Dr. Lalezari is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2300 Sutter St
San Francisco, CA 94115Phone+1 415-353-0800Fax+1 415-353-0801
Education & Training
University of California (San Francisco)/Mount ZionResidency, Internal Medicine, 1986 - 1989
Perelman School of Medicine at the University of PennsylvaniaClass of 1986
Certifications & Licensure
CA State Medical License 1987 - 2025- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Safety Study of MVA Smallpox Vaccine in HIV-positive Subjects Who Are Vaccinia Naive Start of enrollment: 2006 Oct 01
- A Phase 2 Study to Assess the Pharmacokinetics of Bevirimat 100 mg Tablets Given to HIV-1 Positive Patient for 15 Days Start of enrollment: 2008 Nov 01
- Safety, PK and Efficacy of 15 Days of SCY-635 Treatment in Hepatitis C Patients Start of enrollment: 2007 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19.Harish Seethamraju, Otto O Yang, Richard Loftus, Onyema Ogbuagu, Daniel Sammartino
Clinical Therapeutics. 2024-11-01 - 2 citationsBictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV.Felicia L Sterman, Jacob P Lalezari, Ula M Kowalczyk, David W Main, Edward M Grant
AIDS. 2023-06-01 - 5 citationsEDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B.Jordan J Feld, Eric Lawitz, Tuan Nguyen, Jacob Lalezari, Tarek Hassanein
Antiviral Therapy. 2022-12-01
Press Mentions
Remarkable Turnaround Following Leronlimab Treatment in Critically Ill COVID-19 Patient After 84 Days on ECMO; Case Study Published in Journal of Translational AutoimmunityMarch 29th, 2021- CytoDyn to Hold Webcast on October 20 to Discuss DSMC's Recommendations from the Interim Analysis of the Phase 2b/3 Clinical Trial for Severe-to-Critical COVID-19 PatientsOctober 17th, 2020
- CytoDyn to Hold Conference Call on September 16 to Provide Update on Discussions with FDA and MHRA for COVID-19 and FDA Meeting on BLA FilingSeptember 10th, 2020
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
